Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis - PubMed (original) (raw)

. 2003 Aug 1;188(3):458-64.

doi: 10.1086/376510. Epub 2003 Jul 14.

Affiliations

• PMID: 12870129
• DOI: 10.1086/376510

Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis

Henry W Murray et al. J Infect Dis. 2003.

Abstract

In established Leishmania donovani visceral infection in normal mice, anti-interleukin (IL)-10 receptor (IL-10R) monoclonal antibody (MAb) treatment induced intracellular parasite killing within liver macrophages. IL-10R blockade maintained IL-12 protein 40, markedly increased interferon (IFN)-gamma serum levels, and enhanced tissue inducible nitric oxide synthase (iNOS) expression and granuloma assembly. Optimal MAb-induced killing, including synergism with antimony chemotherapy, required endogenous IL-12 and/or IFN-gamma and at least one IFN-gamma-regulated macrophage mechanism-iNOS or phagocyte oxidase. However, in IFN-gamma knockout mice, anti-IL-10R also induced both granuloma formation and leishmanistatic activity. As judged by IL-10R blockade, endogenous IL-10 primarily regulates killing in L. donovani infection by suppressing production of and responses to the Th1 cell-type cytokines, IL-12, and IFN-gamma. However, because anti-IL-10R also released IFN-gamma-independent effects, IL-10 appears to act more broadly and suppresses multiple antileishmanial mechanisms.

PubMed Disclaimer

Similar articles

• Interleukin 10 receptor blockade--pentavalent antimony treatment in experimental visceral leishmaniasis.
  Murray HW. Murray HW. Acta Trop. 2005 Mar;93(3):295-301. doi: 10.1016/j.actatropica.2004.11.008. Acta Trop. 2005. PMID: 15716043
• Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy.
  Murray HW, Lu CM, Mauze S, Freeman S, Moreira AL, Kaplan G, Coffman RL. Murray HW, et al. Infect Immun. 2002 Nov;70(11):6284-93. doi: 10.1128/IAI.70.11.6284-6293.2002. Infect Immun. 2002. PMID: 12379707 Free PMC article.
• Tissue granuloma structure-function in experimental visceral leishmaniasis.
  Murray HW. Murray HW. Int J Exp Pathol. 2001 Oct;82(5):249-67. doi: 10.1046/j.1365-2613.2001.00199.x. Int J Exp Pathol. 2001. PMID: 11703536 Free PMC article. Review.
• Cytokines and nitric oxide as effector molecules against parasitic infections.
  Liew FY, Wei XQ, Proudfoot L. Liew FY, et al. Philos Trans R Soc Lond B Biol Sci. 1997 Sep 29;352(1359):1311-5. doi: 10.1098/rstb.1997.0115. Philos Trans R Soc Lond B Biol Sci. 1997. PMID: 9355122 Free PMC article. Review.

Cited by

• Immunotherapy and immunochemotherapy in combating visceral leishmaniasis.
  Yadagiri G, Singh A, Arora K, Mudavath SL. Yadagiri G, et al. Front Med (Lausanne). 2023 May 17;10:1096458. doi: 10.3389/fmed.2023.1096458. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37265481 Free PMC article. Review.
• T Lymphocyte Exhaustion During Human and Experimental Visceral Leishmaniasis.
  Costa-Madeira JC, Trindade GB, Almeida PHP, Silva JS, Carregaro V. Costa-Madeira JC, et al. Front Immunol. 2022 May 2;13:835711. doi: 10.3389/fimmu.2022.835711. eCollection 2022. Front Immunol. 2022. PMID: 35585983 Free PMC article. Review.
• The Role of MIF and IL-10 as Molecular Yin-Yang in the Modulation of the Host Immune Microenvironment During Infections: African Trypanosome Infections as a Paradigm.
  Stijlemans B, Schoovaerts M, De Baetselier P, Magez S, De Trez C. Stijlemans B, et al. Front Immunol. 2022 Apr 7;13:865395. doi: 10.3389/fimmu.2022.865395. eCollection 2022. Front Immunol. 2022. PMID: 35464430 Free PMC article. Review.
• IL-10 Receptor Blockade Delivered Simultaneously with Bacillus Calmette-Guérin Vaccination Sustains Long-Term Protection against Mycobacterium tuberculosis Infection in Mice.
  Dwivedi V, Gautam S, Headley CA, Piergallini T, Torrelles JB, Turner J. Dwivedi V, et al. J Immunol. 2022 Mar 15;208(6):1406-1416. doi: 10.4049/jimmunol.2100900. Epub 2022 Feb 18. J Immunol. 2022. PMID: 35181640 Free PMC article.
• Leishmaniasis: where are we and where are we heading?
  Sasidharan S, Saudagar P. Sasidharan S, et al. Parasitol Res. 2021 May;120(5):1541-1554. doi: 10.1007/s00436-021-07139-2. Epub 2021 Apr 7. Parasitol Res. 2021. PMID: 33825036 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations

• Research Materials

  • NCI CPTC Antibody Characterization Program